Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT03871439 | OPEN LABEL, 2-PERIOD STUDY, TO COMPARE BIO-AVAILABILITY OF 2 DIFFERENT FORMULATIONS OF PF-05221304 IN HEALTHY ADULTS | PHASE1 | COMPLETED | 10 | — | — | Mar 13, 2019 | May 8, 2019 | May 20, 2020 | 1 | United States |
Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast)
Maximum Observed Plasma Concentration (Cmax)
| Arm | Type | Description |
|---|---|---|
| PF-05221304 Formulation A | EXPERIMENTAL | - |
| PF-05221304 Formulation B | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| PF-05221304 Formulation A | DRUG | 50mg |
| PF-05221304 Formulation B | DRUG | 50mg |
Inclusion Criteria: * Ages of 18 and 55 years old inclusive * Body Mass Index (BMI) of \>= 17.5 and \<= 30.4 kg/m2 * Total body weight \> 50 kg (110lb) Exclusion Criteria: * Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular,...